Adebrelimab
- Generic Name
- Adebrelimab
- Drug Type
- Biotech
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Atridia Pty Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT03133247
- Locations
- 🇦🇺
Linear Clinical Research, Perth, West Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath